- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Anifrolumab considerably improves outcomes in refractory discoid lupus erythematosus
A new article published in the Journal of American Medical Association suggests that in a short retrospective research, every patient with discoid lupus erythematosus (DLE) who had not reacted to many common treatments showed considerable improvement when given anifrolumab (Saphnelo).
DLE is a kind of chronic cutaneous lupus that can leave people with permanent scarring and deformity. An interesting result from one of the pivotal trialsopens in a new tab or window supporting anifrolumab's approval for systemic lupus in 2021, according to Shaw and colleagues, was that 49% of patients taking the medication demonstrated at least a 50% reduction in skin manifestations, as opposed to 25% of the placebo group. A monoclonal antibody, anifrolumab targets the type 1 interferon receptor subunit 1 and has a distinct mode of action. As type 1 interferon expression is known to be correlated with the activity of the DLE illness, they proposed that anifrolumab would be a suitable treatment for DLE patients.
The mean scores on the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity subscale decreased by 65% among eight patients who received anifrolumab treatment for at least eight weeks. The researchers reported their findings in JAMA Dermatology opens in a new tab or window. All patients saw some drop in CLASI activity levels, ranging from 46% to 79%. In every instance, patients assessed their pain and itchiness as "much better" and no side effects were noted.
A collection of before-and-after images of one "representative" patient, a Black lady in her 40s, were included in this piece. The woman had crusty lesions on her arms, head, and chest, as well as full baldness on her scalp before beginning anifrolumab. After using the medication for two months, the scaling was virtually gone. By month six, the researchers said, her daily prednisone dosage had been reduced from 10 mg to 2 mg. Nonetheless, there were still patches of hyper- and hypo-pigmentation, and there was no sign of hair regrowth. This was anticipated in situations of chronic DLE since certain consequences, such scarring, are irreversible. No patient in the research really had a decrease in their score on the 56-point CLASI damage subscale of more than two points.
These preliminary findings show promise for anifrolumab as a treatment alternative for DLE patients, particularly those with severe or resistant illness. To verify the advantage, they urged bigger prospective trials.
Reference:
Shaw, K., Sanchez-Melendez, S., Taylor, D., Barker, J., LaChance, A., Shahriari, N., & Vleugels, R. A. (2023). Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus. In JAMA Dermatology. American Medical Association (AMA). https://doi.org/10.1001/jamadermatol.2023.0175
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751